I can’t answer this as asked because the information you provided doesn’t include any details about (1) what “Aurobindo’s process” refers to (manufacturing steps, starting materials, reagents/conditions, or the specific product/batch) or (2) what outcome you’re comparing against (clonazepam itself vs. an intermediate vs. a polymorph/impurity profile).
Clonazepam is a specific chemical structure (a benzodiazepine). A manufacturer’s process typically does one of these:
- Creates clonazepam from a defined chemical synthesis route (changing intermediates, not the final intended drug structure).
- Controls solid-state form (polymorph), particle size, or impurities (which can affect properties but not the core molecule).
- Adjusts purification/crystallization to meet specifications (again, changing impurities and physical form rather than the core molecular structure).
To explain “how the process alters the molecular structure,” I need at least one of the following:
1) The patent/application or regulatory filing you mean (USPTO/WO, Indian patent, DMF, etc.), or a link or document name/number.
2) The specific Aurobindo product/process description (e.g., “manufacturing method A/B” from a label or patent).
3) What exact structural change you’re expecting or claim you saw (e.g., “isomerization,” “salt formation,” “prodrug,” “impurity formation,” “polymorph change,” etc.).
If you paste the relevant excerpt or provide a link/document identifier, I can map each step to what it would do chemically (e.g., whether it changes functional groups, stereochemistry, salt form, or only purification/solid form).